Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P11168
UPID:
GTR2_HUMAN
Alternative names:
Glucose transporter type 2, liver
Alternative UPACC:
P11168; A8K481; B2R936; B7Z547; F8W8V8; Q9UCW9
Background:
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2), also known as Glucose transporter type 2, liver, plays a pivotal role in glucose homeostasis. It facilitates the transport of glucose, fructose, and galactose across cell membranes, contributing to glucose uptake by hepatocytes and beta cells. This protein is also involved in the transcellular transport of glucose in the small intestine and kidney, and can transport dehydroascorbate.
Therapeutic significance:
SLC2A2's dysfunction is linked to Fanconi-Bickel syndrome, a rare disease characterized by hepatorenal glycogen accumulation and impaired glucose utilization. Understanding the role of SLC2A2 could open doors to potential therapeutic strategies for this condition.